公司资料
Dr. Reddy's Laboratories Ltd 股价、新闻与催化剂
- 股票代码:
- RDY
- 交易所:
- NYSE
- 行业:
- Biopharma
- 所在地:
- India and listed in the U
股票表现
12.11 USD (-1.30%)
收盘价
最后更新: 2026年8月17日
10.8B USD
市值
股价为何变动
As of Aug 17, 2026, RDY closed down 1.30% at $12.11. No new same-company headline was identified in the current news window.
公司概览
业务概览
Dr. Reddy’s Laboratories is a global pharmaceutical company with a broad mix of generics, biosimilars, and specialty products. Its business is defined by scale, manufacturing, and a diversified international footprint.
所在地与行业分类
Headquartered in India and listed in the U.S. as an ADR, Dr. Reddy’s has a large global presence across emerging and developed markets. It sits in generics and diversified pharmaceuticals rather than biotech.
商业模式特征
The company generates value through product volume, manufacturing execution, and portfolio breadth across regulated and emerging markets. Investors watch pricing pressure, product launches, and margin discipline.
生物医药行业定位
Dr. Reddy’s is not a biotech company, but it is relevant to the broader pharma landscape because it participates in biosimilars and global drug supply. Its stock is driven by manufacturing and commercial execution, not clinical catalysts.
未来催化剂
- Dr. Reddy’s catalysts are US generics execution, biosimilar filings, and continued margin discipline. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。